The folks at your fave chemgenex may well get their clocks cleaned by them and i believe they've been misling you (based on some of your comments).
I'm not sure what you think Berger lied about. But the controversy with the board was about a subsidiary that owned some i.p. connected to the mTOR inhibitor. They exchanged shares for the subsidiary. Berger thought the payout should be more than they ended up getting. Whole thing didn't smell right. But that's what can happen when a ceo is also the chairman. At least the board shot him down on that.
News 
Market Data 
Discover 
